Vomaris Innovations
Vomaris Innovations is a private medical device company that develops and commercializes bioelectric wound care products powered by its proprietary V.Dox microcurrent technology, serving prescription, orthopedic, military, and over-the-counter consumer segments through direct sales, an exclusive Arthrex partnership, and e-commerce channels.
- Company typePrivate
- Founded2004
- HeadquartersTempe, United States
- Headcount11–50
- GTM typeB2B and B2C
- OfferingHardware or Manufacturing
What Vomaris Innovations does
Vomaris Innovations, Inc. is a Tempe, Arizona-based private medical device company founded in 2004 that develops and commercializes bioelectric wound care products powered by its proprietary V.Dox Technology platform. The core technology uses a patented matrix of moisture-activated microcell batteries composed of elemental silver and elemental zinc embedded in a substrate; contact with a conductive medium such as saline or wound hydrogel triggers a REDOX reaction that generates a wireless microcurrent field mimicking the skin's natural transepithelial potential and current of injury, intended to support cell migration, re-epithelialization, and antimicrobial activity against biofilm-forming and antibiotic-resistant bacteria. The company monetizes through four distinct revenue streams: prescription-only Procellera Antimicrobial Wound Dressings sold direct to healthcare professionals; JumpStart-branded antibacterial wound dressings distributed through an exclusive global partnership with Arthrex across orthopedic, sports medicine, spine, and cardiothoracic surgery channels; over-the-counter PowerHeal Bioelectric Bandages sold direct-to-consumer via powerhealbandage.com and Amazon; and licensing royalties plus dedicated military distribution through Lovell Gov for combat and tactical applications. The company is privately held, operates as a portfolio entity under Arthrex, Inc., and is led by President and CEO Michael P. Nagel, who has held the role since 2012.
Vomaris Innovations firmographics
Firmographics- Name
- Vomaris Innovations
- Legal name
- Vomaris Innovations, Inc.
- Website
- https://vomaris.com
- Company type
- Private
- Founded year
- 2004
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- Vomaris Innovations is a private medical device company that develops and commercializes bioelectric wound care products powered by its proprietary V.Dox microcurrent technology, serving prescription, orthopedic, military, and over-the-counter consumer segments through direct sales, an exclusive Arthrex partnership, and e-commerce channels.
- Ownership category
- akta.pro rank
Vomaris Innovations industry classification
Industry- Product category
- Advanced Wound Care Devices
- NAICS
- Electromedical and Electrotherapeutic Apparatus Manufacturing (334510), Surgical and Medical Instrument Manufacturing (339112), Surgical Appliance and Supplies Manufacturing (339113)
- SIC
- Electromedical & Electrotherapeutic Apparatus (3845), Surgical & Medical Instruments & Apparatus (3841), Orthopedic, Prosthetic & Surgical Appliances & Supplies (3842)
- akta.pro primary industry
- Antimicrobial Wound Care (Silver/Iodine/PHMB Dressings, Wound Irrigation) (HLAHALAC)
- akta.pro secondary industries
- Advanced Wound Dressings (Foam, Hydrocolloid, Alginate, Hydrogel, Film) (HLAHALAA), First Aid & Wound Care (Bandages, Dressings, Antiseptics, Burn Care) (CRADAMAB), Wound Care & Diabetic Foot Infection (HLAKAGAK)
Keywords
Where Vomaris Innovations is headquartered
LocationHeadquarters
- HQ city
- Tempe
- HQ country
- United States
- HQ region
- North America
Offices2 records
Markets served
Vomaris Innovations business model
Business model- GTM type
- B2B and B2C
- Offering type
- Hardware or Manufacturing
- Cost components
- Supply Chain, Personnel, Technology or R&D, Marketing or Sales, Operations
Revenue model
- Prescription Wound Care Products: Procellera Antimicrobial Wound Dressings sold via prescription to healthcare professionals and hospitals for management of partial and full-thickness wounds across multiple medical and surgical specialties.
- OTC Consumer Products: PowerHeal Antibacterial Bioelectric Bandages sold directly to consumers over-the-counter for superficial wounds via powerhealbandage.com and Amazon.
- Orthopedic/Sports Medicine Products: JumpStart Antibacterial Wound Dressings distributed exclusively through Arthrex for orthopedic surgery, sports medicine, spine, and cardiothoracic surgery applications.
- Licensing Royalties: Licensing arrangement with Arthrex for exclusive global distribution rights in orthopedics and sports medicine markets.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| One time/ perpetual license | Pay-as-you-go | Prescription Products - Procellera |
| Unit Pricing | Pay-as-you-go | OTC Consumer Products - PowerHeal |
| One time/ perpetual license | Pay-as-you-go | Orthopedic Products - JumpStart via Arthrex |
Go-to-market motion3 records
Distribution channels5 records
Marketing channels8 records
Vomaris Innovations product offering
Product offeringCore offering
Vomaris Innovations develops and commercializes bioelectric wound care products powered by its proprietary V.Dox Technology. The platform uses moisture-activated microcell batteries (elemental silver and zinc) that generate wireless microcurrents via a REDOX reaction to mimic the skin's natural transepithelial potential, providing antimicrobial protection and supporting wound healing. The company sells prescription Procellera dressings to healthcare providers, OTC PowerHeal bandages to consumers, and JumpStart dressings to orthopedic surgeons through Arthrex.
Product overview
Vomaris Innovations offers a portfolio of bioelectric wound care products powered by V.Dox™ Technology—a proprietary platform using moisture-activated microcell batteries (elemental silver and zinc) that generate microcurrents mimicking the skin's natural electrical energy. The core products include Procellera® Antimicrobial Wound Dressings (prescription) and PowerHeal™ Bioelectric Bandages (OTC), with specialized versions for orthopedics (JumpStart® via Arthrex), post-surgical care (Procellera FlexEFit™, Procellera Helix Post-Op®), and athletic performance (PERFORM compression garments). The technology platform has demonstrated efficacy against biofilm-forming and antibiotic-resistant bacteria without the use of antibiotics.
Differentiator
Problem solved
Functional benefit
Brands
- V.Dox Technology: Patented bioelectric technology platform using moisture-activated microcell batteries to generate microcurrents for wound healing and antimicrobial protection.
- Procellera FlexEFit
- JumpStart
Products and services
- Procellera Antimicrobial Wound Dressings Prescription-only bioelectric wound dressing powered by V.Dox Technology, using moisture-activated microcell batteries (silver and zinc) to generate microcurrents that mimic the skin's natural electrical energy. Sold to healthcare professionals and hospitals for management of partial and full-thickness wounds, including chronic wounds, surgical site infections, and burns.
- PowerHeal Bioelectric Bandages Over-the-counter bioelectric bandage for superficial wounds. World's first and only OTC bioelectric bandage, powered by V.Dox Technology. Available at powerhealbandage.com and Amazon for individual consumers.
- JumpStart Antibacterial Wound Dressings Branded version of Procellera distributed exclusively by Arthrex for orthopedic surgery, sports medicine, spine, and cardiothoracic surgery applications. Provides post-surgical infection prevention and accelerated wound healing.
- Procellera FlexEFit Antibacterial Wound Dressing Post-surgical wound dressing with 'Link & Build' design that can be configured during application to seamlessly cover incisions of virtually any length or curvature with one product configuration. Used by orthopedic surgeons for post-surgical wound management.
- Procellera Helix Post-Op Post-operative surgical dressing applied directly over sutures, staples, steri-strips and liquid skin adhesives. Features stress-shielding design to reduce suture site stress and improve healing outcomes.
- OrthoElite Product line designed specifically to contour and move with various joints for orthopedic applications. Distributed through Arthrex partnership.
Quantifiable outcome
- 45.5% improvement in healing time vs standard of care (19.8 days vs 36.3 days)
- +6 more outcomes
Companies that use Vomaris Innovations
Customer profileNamed customers7 records
Segments7 records
Ideal customer profiles4 records
Vomaris Innovations technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature3 records
Vomaris Innovations partnerships and signals
Strategic signalPartnerships
Eight partnerships are on record, tiered core and minor.
- Indiana University School of MedicinecoreCollaborative research on biofilm in burn wounds. Blinded sample analysis conducted at Indiana Center for Regenerative Medicine and Engineering under Dr. Sashwati Roy.
- Brooke Army Medical Center / U.S. Army Institute of Surgical Research Burn CentercoreRandomized controlled clinical trial on bioelectric technology effectiveness against burn wound biofilm infection. Led by Dr. Rodney Chan.
- The Ohio State University Wexner Medical CentercoreLeading research on anti-biofilm efficacy, mechanism of action, and wound healing outcomes. Dr. Chandan Sen leads Comprehensive Wound Center research.
- Challenged Athletes Foundation (CAF)minorPartnership to support CAF Elite Paratriathlon Team with Procellera wound dressings for training and competition injuries. Renewed partnership for second year of support.
- Arthrex, Inc.coreExclusive global commercial and development partnership for Procellera technology in orthopedics and sports medicine markets. Arthrex distributes products under JumpStart brand name. Arthrex is a global medical device company operating in over 90 countries.
- U.S. Army Medical Materiel Command (USAMMA)core$1 million research grant to fund clinical study evaluating Procellera versus current Army methods on acute wound healing in U.S. Army Rangers at Fort Benning, Georgia.
- Henry M. Jackson Foundation for the Advancement of Military Medicine (HJF)coreResearch collaboration including data management, regulatory support, site monitoring, and quantitative analysis on biomarkers and bacteriology. Partner on Combat Wound Initiative with Walter Reed.
- Walter Reed National Military Medical CentercoreCombat Wound Initiative study assessing clinical efficacy of bioelectric dressing on chronic soft tissue wound healing rate over 12-week treatment period.
Scale indicators8 records
Recent moves6 records
Expansion highlights5 records
Vomaris Innovations competitors and assessment
Company assessmentBroad incumbents
- Smith+Nephew: Global medical device incumbent with a major Advanced Wound Management franchise (Allevyn, PICO single-use NPWT, ACTICOAT). Competes directly with Vomaris in antimicrobial and advanced wound dressings sold to hospitals and clinicians, and dwarfs Vomaris in commercial reach.
- 3M Health Care (Solventum): Owns the V.A.C. negative pressure wound therapy franchise and a broad advanced wound care portfolio, making it one of the largest scaled players in the same hospital wound care channel where Vomaris sells Procellera and JumpStart.
- Convatec: Pure-play advanced wound care and ostomy company with brands such as Aquacel and FoamLite. Directly comparable product portfolio in antimicrobial and moisture-management dressings, sold through the same hospital formularies and home care channels Vomaris targets.
- Mölnlycke Health Care: Swedish wound care specialist behind the Mepilex, Mepitel and Avance NPWT lines, with deep operating-room and burn care presence. Competes directly with Vomaris in post-surgical and chronic wound dressings globally.
- Coloplast: Danish medical device leader in wound care (Biatain, Conveen) and ostomy. Shares the same chronic wound care customer base and pursues adjacent antimicrobial and bio-active dressing technologies that overlap with Vomaris's positioning.
- B. Braun: Global medical device and IV solutions manufacturer with a meaningful wound care portfolio (Askina, Prontosan). Competes with Vomaris in hospital-acquired wound care and shares the European/international channels relevant to global expansion.
Direct peers
- Organogenesis: US-listed regenerative medicine company commercializing skin substitutes and active wound care biologics (Apligraf, Dermagraft, PuraPly). Closest publicly traded analog to Vomaris in selling clinically differentiated, premium-priced advanced wound therapies to the same wound care clinicians.
- MiMedx: Regenerative wound care and surgical recovery company selling dehydrated amniotic tissue allografts (EpiFix, AmnioFix). Competes for the same surgical wound care and chronic wound care prescribers and shares Vomaris's premium-pricing, evidence-led go-to-market.
- Integra LifeSciences: Specialty medical device company with a dedicated Wound Care and Surgical Reconstruction franchise (Integra dermal regeneration templates, PriMatrix, AmnioExcel). Sells into the same burn, reconstructive and surgical wound care channels Vomaris targets.
Others
- Cardinal Health: Major medical products distributor and manufacturer with wound care products (e.g., Kendall AMD antimicrobial dressings, Cardinal Health-brand dressings). Comparable primarily as a distribution and dressing competitor in US hospitals and home health.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks6 records
Key highlights7 records
Customer concentration
Vomaris Innovations social profiles
Digital presenceVomaris Innovations compliance and trust
Trust signalCompliance1 record
Vomaris Innovations financial estimates
Financial estimateRevenue estimate
Valuation estimate
Vomaris Innovations leadership team
Management profileNumber of profiles
Profiles5 records
Vomaris Innovations funding detail
Funding detailFunding overview
Funding rounds6 records
Investors1 record
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Vomaris Innovations M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Vomaris Innovations
What does Vomaris Innovations do?
Vomaris Innovations develops and commercializes bioelectric wound care products powered by its proprietary V.Dox Technology. The platform uses moisture-activated microcell batteries (elemental silver and zinc) that generate wireless microcurrents via a REDOX reaction to mimic the skin's natural transepithelial potential, providing antimicrobial protection and supporting wound healing. The company sells prescription Procellera dressings to healthcare providers, OTC PowerHeal bandages to consumers, and JumpStart dressings to orthopedic surgeons through Arthrex.
Is Vomaris Innovations a public or private company?
Vomaris Innovations is a private company. It is classified as corporate owned and is currently operating.
When was Vomaris Innovations founded?
Vomaris Innovations was founded in 2004. It employs 11 to 50 people.
Where is Vomaris Innovations based?
Vomaris Innovations is headquartered in Tempe, United States, in the North America region.
How does Vomaris Innovations make money?
Four revenue lines are on record. Prescription Wound Care Products are the primary driver. The others are OTC Consumer Products, orthopedic/Sports Medicine Products and licensing Royalties.
Who are Vomaris Innovations's main competitors?
Broad incumbents on record are Smith+Nephew, 3M Health Care (Solventum), Convatec, Mölnlycke Health Care, Coloplast and B. Braun. Direct peers are Organogenesis, MiMedx and Integra LifeSciences. Cardinal Health is listed as an others.
Does Vomaris Innovations have an API?
No public API is recorded for Vomaris Innovations.
What industry is Vomaris Innovations in?
Vomaris Innovations's product category is Advanced Wound Care Devices. Its primary akta.pro industry code is HLAHALAC, Antimicrobial Wound Care (Silver/Iodine/PHMB Dressings, Wound Irrigation), with a secondary code of HLAHALAA, Advanced Wound Dressings (Foam, Hydrocolloid, Alginate, Hydrogel, Film). Its NAICS code is 334510 and its SIC code is 3845.